CDH1 and skin cancer: Many factors such as mutations, proteolytic cleavage, chromosomal deletions, epigenetic regulation, and transcriptional silencing of the CDH1 promoter, were shown to impede the functionality of E-cadherin during the development of several malignancies including gastric, breast, liver, pancreas, and skin cancers [41].